Skip to content
HomeLatest newsStatement on the release of the Janssen U.S. Transparency Report
Beerse Scientists

Statement on the release of the Janssen U.S. Transparency Report

Share Article
share to

Below, please find a statement on the Janssen U.S. Transparency Report from Joaquin Duato, Johnson & Johnson Executive Vice President and Worldwide Chairman, Pharmaceuticals. You can view the full report on Janssen.com.

“We are pleased to release the inaugural Janssen U.S. Transparency Report, in which we are disclosing more information about our business practices, including those related to pricing. This report builds on our history of responsible pricing practices and our ongoing efforts to provide more transparency into how we operate. These disclosures are steps that we can take as one company as we continue to work with others in the health care system to address stakeholder concerns about U.S. health care costs.” - Joaquin Duato, Executive Vice President and Worldwide Chairman, Pharmaceuticals

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.